Skip Nav Destination
Issues
1 January 2011
-
Cover Image
Cover Image
The cover image is a photomicrograph (400X) showing intact nuclear staining for PMS2 expression in malignant colon cells. PMS2 is one of four mismatch repair proteins, including MLH1, MSH2, and MSH6, that are normally stained for immunohistochemically in screening for Lynch syndrome. Cells in this image were stained using the PMS2 antibody clone A16-4 (BD PharMingen) at a dilution of 1:300. The absence of any one of the four stains in a tumor raises suspicion of an underlying Lynch syndrome mutation in that gene. This staining approach is the most cost-effective method for screening all newly diagnosed colorectal cancer patients for Lynch syndrome. See articles by Dinh et al. (beginning on page 9) and Hampel and de la Chapelle (beginning on page 1) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspectives
Research Articles
Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen–Detected Lung Nodules
Giulia Veronesi; Eva Szabo; Andrea DeCensi; Aliana Guerrieri-Gonzaga; Massimo Bellomi; Davide Radice; Stefania Ferretti; Giuseppe Pelosi; Matteo Lazzeroni; Davide Serrano; Scott M. Lippman; Lorenzo Spaggiari; Angela Nardi-Pantoli; Sergio Harari; Clara Varricchio; Bernardo Bonanni
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.